Trial Profile
Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy AbelZeta Pharma (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 27 Feb 2015 New trial record